Skincare company Galderma posts 25.5% sales leap, driven by US market.
Article excerpt
Highlighted: the sentence this signal was extracted from
Skincare company Galderma posts 25.5% sales leap, driven by US market. Swiss skincare company Galderma said on Thursday that first-quarter sales jumped 25.5% in constant-currency terms to $1.47 billion and signalled it could manage the impact of US tariffs in 2026. The Zug-based group was buoyed by strong demand in the US, where sales surged 41.5% year on year in the January-March period. "Based on the strong start to the year, the guidance is increasingly being de-risked with confidence to navigate a volatile environment," Galderma said in a statement. The results lifted the company's shares, which were up more than 6% shortly before 0900 GMT. Galderma, which was listed on the Swiss stock exchange just over two years ago, said its exposure to US tariffs was expected to remain "manageable" this year. Chief executive Flemming Ornskov said sales of its injectable dermatitis treatment Nemluvio were very strong, with US demand for dermatological skincare products particularly robust on Amazon and other e-commerce platforms. Ornskov told Reuters that Galderma was gaining market share in the US, and was monitoring how companies handled potential refunds linked to tariffs struck down by the US Supreme Court. Any amounts owed would not materially change the group's 2026 financial outlook, he said. Galderma has so far managed to mitigate the impact of the conflict in the Middle...
Keep reading with a free account
The rest of this article, and every signal for Galderma, is in your free account.
